Search for dissertations about: "computed tomography cancer"

Showing result 1 - 5 of 60 swedish dissertations containing the words computed tomography cancer.

2. 1. MRI in prostate cancer : implications for target volume

   Author : Ulrika Björeland; Camilla Thellenberg-Karlsson; Tufve Nyholm; Joakim Jonsson; Lars Beckman; Taran Paulsen Hellebust; Umeå universitet; []
   Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MRI; imaging; prostate; radiotherapy; target detection; radiofysik; radiation physics;

   Abstract : Prostate cancer (PCa) is the most common cancer among men, with 10 000 new cases per year in Sweden [1]. To diagnose PCa, magnetic resonance imaging (MRI) is used to identify and classify the disease. READ MORE

4. 2. Computed tomography, magnetic resonance imaging and positron emission tomography in non-Hodgkin's lymphoma

   Author : Miriam Rodriguez; Uppsala universitet; []
   Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Oncology; NHL; CT; MRI; PET; malignancy grade; prognosis; residual mass; Onkologi; Oncology; Onkologi; diagnostisk radiologi; Diagnostic Radiology;

   Abstract : Certain aspects of the use of computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET) were evaluated in patients with non-Hodgkin'slymphoma (NHL) with the aim of improving the management of these patients.Subjective evaluation of the tumor pattern on CT images, and quantification of tracer uptake using 11C methionine (11C Met) and [18F] fluorodeoxyglucose (18FDG) PET in patients with NHL, were performed to determine their relations to malignancy grade. READ MORE

5. 3. Theranostic Targeting of GRPR and PSMA in Prostate Cancer

   Author : Ayman Abouzayed; Anna Orlova; Ulrika Rosenström; Anzhelika Vorobyeva; Bogdan Mitran; Cristina Müller; Uppsala universitet; []
   Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; prostate cancer; gastrin-releasing peptide receptor GRPR ; prostate-specific membrane antigen PSMA ; nuclear medicine; molecular imaging; radiotracers; theranostics; Farmaceutisk vetenskap; Pharmaceutical Science; Oncology; Onkologi;

   Abstract : This thesis is based on five original articles that investigated the theranostics of prostate cancer by gastrin-releasing peptide receptor (GRPR) and prostate-specific membrane antigen (PSMA) targeting. GRPR and PSMA are two extensively evaluated prostate cancer cell markers due to their overexpression in the majority of prostate cancer samples. READ MORE

6. 4. PET in Prostate Cancer – Detection, Tumour Biology and Prognosis

   Author : Naresh Kumar Regula; Jens Sörensen; Mark Lubberink; Irina Velikyan; Katrine Riklund; Uppsala universitet; []
   Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Prostate cancer; 11C-acetate; 68Ga-PSMA-11; 18F-NaF; PET CT; Radiology; Radiologi;

   Abstract : Prostate cancer (PCa) is the most common non-cutaneous malignancy in men and the leading cause of cancer-related deaths in Sweden. Despite the major advances, the current diagnostic modalities fall short of standards, specifically, precise localization required for effective management of the PCa. READ MORE

7. 5. Monitoring of neuroendocrine tumor patients undergoing systemic therapies

   Author : Olof Pettersson; Anders Sundin; Håkan Geijer; Uppsala universitet; []
   Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Therapy monitoring; NET; neuroendocrine tumor; computed tomography; CT; PRRT; 177Lu-DOTATATE; TGR; tumor growth rate; theranostics; DOTATOC-PET CT; Radiology; Radiologi; Endokrinologi och Diabetologi; Endocrinology and Diabetology; Oncology; Onkologi;

   Abstract : Monitoring of neuroendocrine tumor (NET) patients undergoing systemic therapies is troublesome as biomarkers capable of detecting tumor responses have been difficult to establish. Changes in the sum of target lesion diameters are used to evaluate the effects of therapy according to the response evaluation criteria in solid tumors (RECIST 1.1). READ MORE